Citations

Clear

3942 citation(s) found for "To, Van".

Clinician‐patient communication during the diagnostic workup: The ABIDE project
Visser, Leonie N.C. , Kunneman, Marleen , Murugesu, Laxsini , Maurik, Ingrid S. van , Zwan, Marissa D. , Schuur, Jacqueline, Wind, Hilje A., Blaauw, M., Kragt, Jolijn J, Roks, Gerwin , Boelaarts, Leo, Schipper, Annemieke C, Schooneboom, Niki, Scheltens, Philip , Smets, Ellen M.A. , Scheltens, Philip , Bouwman, Femke H. , Flier, Wiesje M. van der

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | July 29, 2019 | Volume: 11 | Issue: 1 | Pages: 520-528

10.1016/j.dadm.2019.06.001 | PMID 31388556 Get It

AbstractIntroductionWe aimed to describe clinician‐patient communication in the diagnostic process of memory clinics, specifically clinician behavior known to facilitate knowledgeable participation of patients during consultations.MethodsIn this multicenter, observational study, we audio‐recorded routine diagnostic consultations of 41 clinicians and 136 patients/caregivers at eight memory clinics. Patients/caregivers completed surveys after each audiotaped consultation. We used a study‐specific coding scheme to categorize communication behavior.ResultsClinicians often provided information on (results of) diagnostic testing. They infrequently invited questions and/or checked understanding. Clinician behavior to involve patients in decision‐making about diagnostic testing was limited. Of note, patients/caregivers rarely expressed their information or involvement preferences. Yet, approximately, one quarter of them would have liked to receive more information.DiscussionInvolving patients more explicitly by means of shared decision‐making could benefit the quality of care provided in memory clinics because it enables clinicians to attune the diagnostic workup to the individual patient's needs.
Type 8 long QT syndrome: pathogenic variants in CACNA1C-encoded Cav1.2 cluster in STAC protein binding site
Mellor, Greg , Panwar, Pankaj, Lee, Andrea K, Hathaway, Julie , Bartels, Kirsten , Balaji, Seshadri , Roberts, Jason D. , Simpson, Chris S., Boczek, Nicole J. , Tester, David J. , Radbill, Andrew E. , Mok, Ngai‐Shing, Hamilton, Robert M. , Kaufman, Elizabeth S. , Eugenio, Paul, January, Craig T., McDaniel, George, Leather, Richard, Falik, Shelley, Behr, Elijah R. , Wilde, Arthur A.M. , Sanatani, Shubhayan , Ackerman, Michael J. , Petegem, Filip Van , Laksman, Zachary , Behr, Elijah Raphael , Sanatani, Shubhayan , Hamilton, Robert , Steinberg, Christian , Christian, Susan , Weiss, Raul , Erickson, Christopher, Krahn, Andrew D.

Mayo Clinic

EP Europace | July 24, 2019 | Volume: 21 | Issue: 11 | Pages: 1725-1732

10.1093/europace/euz215 | PMID 31408100 Get It

Abstract Aims Pathogenic gain-of-function variants in CACAN1C cause type-8 long QT syndrome (LQT8). We sought to describe the electrocardiographic features in LQT8 and utilize molecular modelling to gain mechanistic insights into its genetic culprits. Methods and results Rare variants in CACNA1C were identified from genetic testing laboratories. Treating physicians provided clinical information. Variant pathogenicity was independently assessed according to recent guidelines. Pathogenic (P) and likely pathogenic (LP) variants were mapped onto a 3D modelled structure of the Cav1.2 protein. Nine P/LP variants, identified in 23 patients from 19 families with non-syndromic LQTS were identified. Six variants, found in 79% of families, clustered to a 4-residue section in the cytosolic II–III loop region which forms a region capable of binding STAC SH3 domains. Therefore, variants may affect binding of SH3-domain containing proteins. Arrhythmic events occurred in similar proportions of patients with II–III loop variants and with other P/LP variants (53% vs. 48%, P = 0.41) despite shorter QTc intervals (477 ± 31 ms vs. 515 ± 37 ms, P = 0.03). A history of sudden death was reported only in families with II–III loop variants (60% vs. 0%, P = 0.03). The predominant T-wave morphology was a late peaking T wave with a steep descending limb. Exercise testing demonstrated QTc prolongation on standing and at 4 min recovery after exercise. Conclusion The majority of P/LP variants in patients with CACNA1C-mediated LQT8 cluster in an SH3-binding domain of the cytosolic II–III loop. This represents a ‘mutation hotspot’ in LQT8. A late-peaking T wave with a steep descending limb and QT prolongation on exercise are commonly seen.
Guidelines for neuromuscular ultrasound training
Tawfik, Eman A. , Cartwright, Michael S. , Grimm, Alexander , Boon, Andrea J. , Kerasnoudis, Antonios , Preston, David C. , Wilder‐Smith, Einar , Axer, Hubertus , Hobson‐Webb, Lisa D., Crump, Nicholas , Shahrizaila, Nortina , Inkpen, Peter, Mandeville, Ross , Sakamuri, Sarada, Shook, Steven J. , Shin, Susan , Walker, Francis O. , Crump, Nicholas , Shin, Susan , Alfen, Nens van

Mayo Clinic

Muscle & Nerve | July 23, 2019 | Volume: 60 | Issue: 4 | Pages: 361-366

10.1002/mus.26642 | PMID 31335971 Get It

AbstractNeuromuscular ultrasound has become an essential tool in the diagnostic evaluation of various neuromuscular disorders, and, as such, there is growing interest in neuromuscular ultrasound training. Effective training is critical in mastering this modality. Our aim was to develop consensus‐based guidelines for neuromuscular ultrasound training courses. A total of 18 experts participated. Expert opinion was sought through the Delphi method using 4 consecutive electronic surveys. A high degree of consensus was achieved with regard to the general structure of neuromuscular ultrasound training; the categorization of training into basic, intermediate, and advanced levels; the learning objectives; and the curriculum for each level. In this study, a group of neuromuscular ultrasound experts established consensus‐based guidelines for neuromuscular ultrasound training. These guidelines can be used in the development of the specialty and the standardization of neuromuscular ultrasound training courses and workshops.
Acquired Idiopathic Stiffness After Total Knee Arthroplasty
Tibbo, Meagan E. , Limberg, Afton K. , Salib, Christopher G. , Ahmed, Ahmed T. , Wijnen, André J. van , Berry, Daniel M. , Abdel, Matthew P. , Berry, Daniel J. , van Wijnen, Andre J , Abdel, Matthew P , Berry, Daniel J , Berry, Daniel J.

Mayo Clinic

Journal of Bone and Joint Surgery | July 18, 2019 | Volume: 101 | Issue: 14 | Pages: 1320-1330

10.2106/jbjs.18.01217 | PMID 31318813 Get It

Background: Stiffness is a common reason for suboptimal clinical outcomes after primary total knee arthroplasty (pTKA). There is a lack of consensus regarding its definition, which is often conflated with its histopathologic subcategory—i.e., arthrofibrosis. There is value in refining the definition of acquired idiopathic stiffness in an effort to select for patients with arthrofibrosis. We conducted a systematic review and meta-analysis to establish a consensus definition of acquired idiopathic stiffness, determine its prevalence after pTKA, and identify potential risk factors for its development. Methods: MEDLINE, Embase, Cochrane Controlled Register of Trials (CENTRAL), and Scopus databases were searched from 2002 to 2017. Studies that included patients with stiffness after pTKA were screened with strict inclusion and exclusion criteria to isolate the subset of patients with acquired idiopathic stiffness unrelated to known extrinsic or surgical causes. Three authors independently assessed study eligibility and risk of bias and collected data. Outcomes of interest were then analyzed according to age, sex, and body mass index (BMI). Results: In the 35 included studies (48,873 pTKAs), the mean patient age was 66 years. In 63% of the studies, stiffness was defined as a range of motion of <90° or a flexion contracture of >5° at 6 to 12 weeks postoperatively. The prevalence of acquired idiopathic stiffness after pTKA was 4%, and this did not differ according to age (4%, I 2 = 95%, among patients <65 years old and 5%, I 2 = 96%, among those ≥65 years old; p = 0.238). The prevalence of acquired idiopathic stiffness was significantly lower in males (1%, I 2 = 85%) than females (3%, I 2 = 95%) (p < 0.0001) as well as in patients with a BMI of <30 kg/m 2 (2%, I 2 = 94%) compared with those with a BMI of ≥30 kg/m 2 (5%, I 2 = 97%) (p = 0.027). Conclusions: Contemporary literature supports the following definition for acquired idiopathic stiffness: a range of motion of <90° persisting for >12 weeks after pTKA in patients in the absence of complicating factors including preexisting stiffness. The mean prevalence of acquired idiopathic stiffness after pTKA was 4%; females and obese patients were at increased risk. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing
Majumder, Shounak , Yab, Tracy C. , Dukek, Brian A. , Cao, Xiaoming , Wu, Chung Wah, Aslanian, Harry R., Castillo, Carlos Fernández-del, Doyle, Leona A. , Farrell, James J. , Fisher, William E., Lee, Yvonne N., Park, Walter G. , Rodrigues, Clifton, Salem, Ronald R. , Simeone, Diane M. , Urs, Sumithra, Buren, George Van , Smyrk, Thomas C. , Allawi, Hatim T. , Lidgard, Graham P. , Chari, Suresh T. , Kendrick, Michael L. , Topazian, Mark , Ahlquist, David A. , Berger, Calise K. , Foote, Patrick H. , Mahoney, Douglas W. , Raimondo, Massimo , Kisiel, John B. , Majumder, Shounak , Taylor, William R. , Lee, Linda , Rodrigues, Clifton, Gould Rothberg, Bonnie E , Chari, Suresh T

Mayo Clinic

American Journal of Gastroenterology | July 15, 2019 | Volume: 114 | Issue: 9 | Pages: 1539-1549

10.14309/ajg.0000000000000284 | PMID 31306149 Get It

OBJECTIVES: Pancreatic cystic lesions (PCLs) may be precancerous. Those likely to harbor high-grade dysplasia (HGD) or pancreatic cancer (PC) are targets for surgical resection. Current algorithms to predict advanced neoplasia (HGD/PC) in PCLs lack diagnostic accuracy. In pancreatic tissue and cyst fluid (CF) from PCLs, we sought to identify and validate novel methylated DNA markers (MDMs) that discriminate HGD/PC from low-grade dysplasia (LGD) or no dysplasia (ND). METHODS: From an unbiased whole-methylome discovery approach using predefined selection criteria followed by multistep validation on case (HGD or PC) and control (ND or LGD) tissues, we identified discriminant MDMs. Top candidate MDMs were then assayed by quantitative methylation-specific polymerase chain reaction on archival CF from surgically resected PCLs. RESULTS: Of 25 discriminant MDMs identified in tissue, 13 were selected for validation in 134 CF samples (21 cases [8 HGD, 13 PC], 113 controls [45 ND, 68 LGD]). A tree-based algorithm using 2 CF-MDMs ( TBX15 , BMP3 ) achieved sensitivity and specificity above 90%. Discrimination was significantly better by this CF-MDM panel than by mutant KRAS or carcinoembryonic antigen, with areas under the receiver operating characteristic curve of 0.93 (95% confidence interval: 0.86–0.99), 0.71 (0.57–0.85), and 0.72 (0.60–0.84), respectively. Cutoffs for the MDM panel applied to an independent CF validation set (31 cases, 56 controls) yielded similarly high discrimination, areas under the receiver operating characteristic curve = 0.86 (95% confidence interval: 0.77–0.94, P = 0.2). DISCUSSION: Novel MDMs discovered and validated in tissue accurately identify PCLs harboring HGD/PC. A panel of 2 MDMs assayed in CF yielded results with potential to enhance current risk prediction algorithms. Prospective studies are indicated to optimize and further evaluate CF-MDMs for clinical use.
Incidence and Management of Olaratumab Infusion-Related Reactions
Govindarajan, Rangaswamy, Attia, Steven , Somaiah, Neeta , Barker, Scott , Shahir, Ashwin, Barrett, Emily, Lee, Pablo , Ramage, Samuel , Tap, William D. , Tine, Brian A. Van , Wacheck, Volker

Mayo Clinic

Journal of Oncology Practice | July 3, 2019 | Volume: 15 | Issue: 11 | Pages: e925-e933

10.1200/jop.18.00761 | PMID 31268811 Get It

PURPOSE:Olaratumab is a human monoclonal immunoglobulin G1 antibody against platelet-derived growth factor receptor-α. We report the nature and frequency of infusion-related reactions (IRRs) with olaratumab in clinical trials and postmarketing reports.METHODS:Data from patients exposed to olaratumab across nine clinical trials were reviewed for IRRs. Blood samples were also analyzed for pre-existing immunoglobulin E anti–galactose-α-1,3-galactose (anti–α-Gal) antibodies.RESULTS:In the clinical trials, IRRs were identified in 70 of 485 patients (14.4%). The most frequent symptoms included flushing, fever or chills, and dyspnea. For 68 of 70 patients (97.1%), the first IRR occurred during the first two cycles of treatment. Grade 3 or worse IRRs were reported in 11 patients (2.3%), all during the first infusion and usually within 15 minutes of the start of the infusion. One IRR-related fatality (0.2%) occurred in a nonpremedicated patient with grade 3 or worse cardiac comorbidities. There was an association between grade 3 or worse IRRs and pre-existing anti–α-Gal antibodies, with a trend toward higher IRR rates in US geographies known to have a higher prevalence of anti–α-Gal antibodies. IRRs in postmarketing reports were consistent in nature and severity with those in the clinical trials.CONCLUSION:Premedication with corticosteroids and antihistamines should occur in all patients before olaratumab infusion, as indicated in labels in the United States and the European Union. Patients receiving olaratumab should be monitored for IRRs in a setting where resuscitation equipment is available for the treatment of IRRs.
Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease
Gastel, Maatje D.A. van , Edwards, Marie E., Torres, Vicente E. , Gansevoort, Ron T. , Kline, Timothy L. , Torres, Vicente E , Erickson, Bradley J.

Mayo Clinic

Journal of the American Society of Nephrology | July 3, 2019 | Volume: 30 | Issue: 8 | Pages: 1514-1522

10.1681/asn.2018090902 | PMID 31270136 Get It

Significance Statement Because renal function often remains stable in the early stages of autosomal dominant polycystic kidney disease (ADPKD), total kidney volume (TKV) is the most important biomarker of disease severity and progression. The authors developed and validated a fully automated method of simultaneously measuring TKV and total liver volume (TLV) as well as their growth rates from magnetic resonance images. Their findings indicate that the method’s performance is equivalent to the gold standard of manual tracing while requiring a fraction of the time and skill. This approach may address the unmet need for rapid and reliable assessment of TKV and TLV, allowing identification of patients with rapidly progressing ADPKD for emerging drug treatments and serving as a reliable alternative for assessment of disease progression in clinical trials. Background The formation and growth of cysts in kidneys, and often liver, in autosomal dominant polycystic kidney disease (ADPKD) cause progressive increases in total kidney volume (TKV) and liver volume (TLV). Laborious and time-consuming manual tracing of kidneys and liver is the current gold standard. We developed a fully automated segmentation method for TKV and TLV measurement that uses a deep learning network optimized to perform semantic segmentation of kidneys and liver. Methods We used 80% of a set of 440 abdominal magnetic resonance images (T2-weighted HASTE coronal sequences) from patients with ADPKD to train the network and the remaining 20% for validation. Both kidneys and liver were also segmented manually. To evaluate the method’s performance, we used an additional test set of images from 100 patients, 45 of whom were also involved in longitudinal analyses. Results TKV and TLV measured by the automated approach correlated highly with manually traced TKV and TLV (intraclass correlation coefficients, 0.998 and 0.996, respectively), with low bias and high precision (<0.1%±2.7% for TKV and −1.6%±3.1% for TLV); this was comparable with inter-reader variability of manual tracing (<0.1%±3.5% for TKV and −1.5%±4.8% for TLV). For longitudinal analysis, bias and precision were <0.1%±3.2% for TKV and 1.4%±2.9% for TLV growth. Conclusions These findings demonstrate a fully automated segmentation method that measures TKV, TLV, and changes in these parameters as accurately as manual tracing. This technique may facilitate future studies in which automated and reproducible TKV and TLV measurements are needed to assess disease severity, disease progression, and treatment response.
Surgical Outcomes of Endoscopic Versus Open Resection for Primary Sinonasal Malignancy: A Meta-analysis
Lu, Victor M. , Ravindran, Krishnan , Smith, Timothy R. , Donaldson, Angela M. , Quiñones‐Hinojosa, Alfredo , Mekary, Rania A. , Chaichana, Kaisorn L. , Phan, Kevin H. , Gompel, Jamie J. Van

Mayo Clinic

American Journal of Rhinology & Allergy | June 20, 2019 | Volume: 33 | Issue: 5 | Pages: 608-616

10.1177/1945892419856976 | PMID 31219311 Get It

Background Endoscopic resection (ER) for uncommon sinonasal malignancies (SNMs) has been reported to confer superior surgical outcomes compared to open resection (OR) based on indirect comparisons of limited evidence. Objective The aim of this study was to pool all direct comparative studies in the literature to validate this potential superior association. Methods Systematic searches of 7 electronic databases from their inception to April 2019 were conducted following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. There were 1001 articles identified for screening. Outcomes of interest were pooled as risk ratios (RRs) and mean difference (MD) and analyzed using a random-effects model. Results There were 10 studies included in this meta-analysis, with 900 SNM patients in total where ER and OR were utilized in 399 (44%) and 501 (56%) cases, respectively. Compared to OR, random-effects (RE) modeling indicated ER resulted in statistically comparable complications (RR = 0.68; P-effect = .12) and recurrence (RR = 0.84; P-effect = .35). ER was associated with significantly shorter length of stay (LOS) compared to OR (MD = −2.9 days; P-effect <.01). Conclusions The use of ER to manage SNM was associated with significantly favorable reduction in LOS compared to OR. However, with respect to other surgical outcomes and recurrence, the current literature does not indicate either ER or OR as statistically superior. Therefore, until greater validation of these associations can be proven, expectations that ER for SNMs confers superior surgical outcomes compared to OR should be tempered.